1. Home
  2. PNNT vs IMUX Comparison

PNNT vs IMUX Comparison

Compare PNNT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PennantPark Investment Corporation

PNNT

PennantPark Investment Corporation

N/A

Current Price

$3.79

Market Cap

251.4M

Sector

Finance

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$16.46

Market Cap

209.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNNT
IMUX
Founded
2007
2016
Country
United States
United States
Employees
N/A
66
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
251.4M
209.2M
IPO Year
2007
2013

Fundamental Metrics

Financial Performance
Metric
PNNT
IMUX
Price
$3.79
$16.46
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$5.75
$36.00
AVG Volume (30 Days)
609.3K
138.7K
Earning Date
05-07-2026
05-14-2026
Dividend Yield
20.87%
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$0.51
52 Week High
$7.29
$16.60

Technical Indicators

Market Signals
Indicator
PNNT
IMUX
Relative Strength Index (RSI) 71.10 64.08
Support Level $3.27 $0.74
Resistance Level $3.92 N/A
Average True Range (ATR) 0.11 1.05
MACD 0.07 0.16
Stochastic Oscillator 100.00 82.70

Price Performance

Historical Comparison
PNNT
IMUX

About PNNT PennantPark Investment Corporation

Pennant Park Investment Corp is a closed-end, non-diversified investment company. Its investment objective is to generate current income and capital appreciation also seeking to preserve capital through debt and equity investments. The company focuses on investing in United States middle-market companies that offer attractive risk-reward to investors and to create a diversified portfolio that includes senior secured debt, mezzanine debt, and equity investments. It generates majority of its revenue from interest and dividends received from investments made.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: